Who are Bromfenac eye drop's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin (acetylsalicylic acid), Prednisone and Aspirin, 0,09% Bromfenac, ABS, Ibuprofen Acid, ketorolac 0.5%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bromfenac-eye-drop.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Bromfenac eye drop — Competitive Intelligence Brief

Bromfenac eye drop (Bromfenac eye drop) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Ophthalmology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Bromfenac eye drop (Bromfenac eye drop) — Azienda USL Reggio Emilia - IRCCS. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bromfenac eye drop TARGET	Bromfenac eye drop	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Aspirin (acetylsalicylic acid)	Aspirin (acetylsalicylic acid)	Swedish Medical Center	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Prednisone and Aspirin	Prednisone and Aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) combination	Glucocorticoid receptor (prednisone); Cyclooxygenase-1 and Cyclooxygenase-2 (aspirin)
0,09% Bromfenac	0,09% Bromfenac	Hospital de La Luz	marketed	Nonsteroidal Anti-Inflammatory Drug (NSAID)	Cyclooxygenase-2 (COX-2)
ABS	ABS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Ibuprofen Acid	Ibuprofen Acid	Reckitt Benckiser Healthcare (UK) Limited	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
ketorolac 0.5%	ketorolac 0.5%	Queen's University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

Università degli Studi di Brescia · 4 drugs in this class
Bausch & Lomb Incorporated · 4 drugs in this class
Bayer · 3 drugs in this class
Pfizer · 3 drugs in this class
Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
Organon and Co · 3 drugs in this class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
Bezmialem Vakif University · 2 drugs in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bromfenac eye drop — Competitive Intelligence Brief. https://druglandscape.com/ci/bromfenac-eye-drop. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab